Biochemical and Biophysical Research Communications
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer
Introduction
Lung cancer is the leading cause of cancer-related deaths in the United States among both men and women [1]. Analysis of the lung cancer genome and proteome has demonstrated that focusing on molecular heterogeneity within lung cancers may be a viable approach to identify and develop novel therapeutics. Aberrant expression of miRNAs in malignancy and their frequent location in fragile chromosomal regions suggests their importance to the pathogenesis of disease [2]. MicroRNAs (miRNAs or miRs) represent a family of small non-coding RNAs (approximately 21–25 nt long) expressed in many organisms including animals, plants, and viruses [3]. MiRNAs are integral to gene regulation, apoptosis, hematopoietic development, and the maintenance of cell differentiation [3], [4]. Researchers have identified abnormal expression of miRNAs in several types of malignancies including lung cancer [5], [6], [7], [8], [9], [10]. MiRNAs have the capacity to target multiple biological functions essential to tumor progression. For example, miR-221 and -222 are upregulated in TNF-α related apoptosis-inducing ligand lung cancer cell lines. Silencing of these miRNAs sensitized resistant cell lines to TRAIL agents [11]. In human lung cancers, particularly small cell carcinoma, miR-17–92 is also over-expressed and in vitro introduction enhanced cell proliferation [12]. Selective silencing of both miR-17–5p and miR-20a induced apoptosis selectively in lung cancer cells over-expressing miR-17–92[13].
MiR-133A and B are currently regarded as are muscle-specific miRNAs [14]. MiR-133A shares a transcriptional unit with miR-1[15]. Through targeting of critical genes involved in cardiac development (Rho-A, Ccd42) and genes involved in cardiac channel expression (HCN2 and HCN4), miR1/133A/133B are implicated in the regulation of cardiac myogenesis and development and cardiac ion channel expression [16], [17]. In addition, both miR-1 and 133 appear to alter cardiomyocyte apoptosis through targeting of HSP60 and 70 [14]. Few if any studies have investigated a potential role for these miRNAs in non-cardiac disease. Recently, Nasser et al. demonstrated that miR-1 was decreased in lung cancer and that over-expression of miR-1 both in vitro and in vivo resulted in reduced tumor growth, migration and increased sensitivity to doxorubicin [18]. Herein, we demonstrate that miR-133B expression is reduced in human non-small cell lung cancer (NSCLC). In addition, miR-133B functionally targets the pro-survival molecules (myeloid cell leukemia 1) MCL-1 and B-cell CLL/lymphoma 2 like 2 (BCL2L2 or BCL-W) and induces apoptosis NSCLC in the setting of chemotherapeutic agents.
Section snippets
Materials and methods
Cell culture and reagents. H23, H2172, H522, H2009, A549 (adenocarcinoma), H226, H1703 (squamous cell) (American Type Culture Collection, Manassas, VA) and primary normal human bronchial epithelial cells (NHBE) (ScienCell, Research Laboratories, Carlsbad, California) were maintained in 37 °C humidified CO2 incubator and grown in appropriate media. Gemcitabine (25 nM) was used for drug treatment experiments (Eli Lilley, Indianapolis, IN).
Western blotting. Cell and tissue lysates were prepared
Differential expression of miR-133B in human NSCLC
In this study, we examined differentially expressed miRNAs in a cohort of 8 cases of matched adenocarcinomas and adjacent uninvolved lung tissue and 4 additional non-paired adenocarcinomas. We used a high throughput qRT-PCR assay [19]. p-Values were obtained and the significance level was determined by controlling the mean number of false positives [20], [21]. Heat-maps of the expression values with hierarchical clustering were generated to aid in visualization. Out of 198 detected miRNA, we
Acknowledgments
This work was supported by National Institutes of Health Grants #HL077717 (S.P.N.) and Chest/LUNGevity Foundation Grant (S.P.N.).
The authors have no conflicts of interest to declare.
The authors would like to thank Drs. Carlo Croce and Melissa Piper for their assistance in the preparation of this manuscript.
References (38)
- et al.
MicroRNAs: a new class of regulatory genes affecting metabolism
Cell Metab.
(2006) - et al.
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
Cancer Cell
(2006) - et al.
Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart
J. Biol. Chem.
(2008) - et al.
Real-time PCR quantification of precursor and mature microRNA
Methods
(2008) - et al.
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets
Cell
(2005) - et al.
MicroRNA targeting specificity in mammals: determinants beyond seed pairing1
Mol. Cell
(2007) - et al.
Prediction of mammalian microRNA targets
Cell
(2003) - et al.
Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway
Eur. J. Pharmacol.
(2004) - et al.
The hallmarks of cancer
Cell
(2000) - et al.
Cancer statistics
CA Cancer J. Clin.
(2009)
Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
Proc. Natl. Acad. Sci. USA
MicroRNAs: fundamental facts and involvement in human diseases
Birth Defects Res. C Embryo Today
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias
Proc. Natl. Acad. Sci. USA
Real-time expression profiling of microRNA precursors in human cancer cell lines
Nucleic Acids Res.
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma
JAMA
Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications
J. Clin. Invest.
MicroRNA gene expression deregulation in human breast cancer
Cancer Res.
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer
Oncogene
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation
Cancer Res.
Cited by (157)
miRNAs orchestration of gallbladder cancer – Particular emphasis on diagnosis, progression and drug resistance
2023, Pathology Research and PracticeTherapeutic advancements in targeting BCL-2 family proteins by epigenetic regulators, natural, and synthetic agents in cancer
2023, European Journal of PharmacologyNon-coding RNAs and glioblastoma: Insight into their roles in metastasis
2022, Molecular Therapy OncolyticsThe role of non-coding RNAs in ferroptosis regulation
2022, Journal of Trace Elements in Medicine and BiologyMyeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy
2021, International Journal of Biological Macromolecules